Serious GLP-1 injuries: what to document and how review requests work
If Ozempic, Wegovy, or another GLP-1 drug left you with stomach paralysis, pancreatitis, severe vomiting, vision loss, or another major complication, start with the drug, the timing, the injury, and the medical care that followed.
Covered here
Serious injuries only
Focused on stomach paralysis, pancreatitis, severe vomiting, vision loss, rash, pregnancy exposure, and thyroid warnings.
Real source citations
Current FDA labels, NIH pages, and agency guidance are cited throughout the site.
Clear first step
Start with the drug, the timing, the main symptoms, and the care you needed.
17+
Focused topic pages
FDA + NIH + Courts
Primary public sources
Updated
Reviewed April 2026
Main Topics
Start with the page closest to what happened
These pages separate stomach symptoms, vision concerns, pancreatitis questions, and documentation so the information stays specific instead of collapsing into one broad overview.
Condition Page
Stomach paralysis and gastroparesis
Persistent nausea, vomiting, early fullness, bloating, delayed gastric emptying, and stomach paralysis claims.
Condition Page
Vision loss and retinopathy
Blurry vision, retinal changes, diabetic retinopathy complications, and urgent eye symptoms.
Resource Page
Serious GLP-1 side effects
Common reactions, red-flag symptoms, and where stomach, vision, rash, and thyroid issues break out into separate pages.
Process Page
How a review usually starts
What details usually matter first, what records help, and what a short intake can and cannot answer.
Key References
Label warnings, records, studies, and court updates
These pages collect current label language, record guidance, published studies, and court developments behind the main GLP-1 injury topics covered here.
Safety Guide
GLP-1 recall and counterfeit product questions
What FDA has actually said about counterfeit Ozempic, unapproved GLP-1 products, and why that is different from a blanket recall.
Medication Guide
Exenatide, Byetta, and Bydureon
Current exenatide label warnings on pancreatitis, kidney injury, severe GI reactions, and the extended-release thyroid boxed warning.
Vision Guide
NAION and sudden vision loss
What current studies, regulators, and the new MDL say about NAION and semaglutide.
Condition Page
Pancreatitis
Upper-abdominal pain, vomiting, warning language, and when pancreatitis becomes a real medical question.
Condition Page
Dehydration and volume depletion
Persistent vomiting, diarrhea, kidney-risk warnings, and the signs that turn a bad GI episode into an urgent fluid-loss problem.
Condition Page
Bowel obstruction and ileus
When severe bloating, constipation, vomiting, and inability to pass stool or gas become a different problem from routine nausea.
Condition Page
Gallbladder attacks and gallstones
What the current label says about acute gallbladder disease and what symptoms or records matter most.
Medication Guide
Ozempic
What Ozempic is for, how it is dosed, and the main warnings in the current label.
Documentation Guide
What records matter most
Medication history, ER notes, imaging, eye exams, pharmacy fills, and billing records that help anchor the timeline.
Documentation Guide
How to document severe GI symptoms
A usable timeline for nausea, vomiting, dehydration, abdominal pain, ER visits, and follow-up care.
Legal Landscape
Current GLP-1 lawsuit updates
The active federal MDLs, recent FDA changes, and the injury categories drawing the most attention.
Reference Page
GLP-1 labels, studies, and current developments
A central page for labels, litigation, trials, and recent safety developments.
Chronology
Recent GLP-1 updates
A dated timeline of label changes, court developments, and regulator actions shaping the current GLP-1 picture.
Other Topics
Other issues we cover
Rash, pregnancy, gout, mental-health concerns, and thyroid warnings each have a separate page, so the information stays specific instead of getting buried in one broad side-effects summary.
Dehydration and kidney-stress questions
Persistent vomiting, dark urine, weakness, IV fluids, kidney-function labs, and volume-depletion warnings.
Read pageBowel obstruction and ileus
Severe bloating, constipation, distention, vomiting, and the difference between obstruction, ileus, and delayed gastric emptying.
Read pageGallbladder attacks and gallstones
Upper-right abdominal pain, ultrasound findings, gallstones, cholecystitis, and current acute gallbladder disease warnings.
Read pageRash and allergic reactions
Rash, hives, swelling, breathing symptoms, and hypersensitivity warnings after semaglutide use.
Read pageGout and uric-acid reports
What the current evidence says about gout, dehydration, uric acid, and semaglutide.
Read pagePregnancy exposure
Pregnancy warnings, planned pregnancy timing, and current Wegovy label language.
Read pagePancreatitis and severe abdominal pain
Upper-abdominal pain, vomiting, pancreatitis warnings, and the records that matter most.
Read pageOzempic label and safety overview
What Ozempic is, what the label says, how dose escalation works, and where the major warnings appear.
Read pageMood changes and self-harm warnings
Current FDA positioning after the 2026 warning removal and when urgent mental-health care comes first.
Read pageThyroid tumor warning
The boxed warning on thyroid C-cell tumors, what it says, and what it does not say.
Read pageWhat To Have Ready
The first details that make your situation easier to understand
Drug and dose history
The first thing to pin down is which GLP-1 drug you took, when you started, and whether the dose had changed.
What happened medically
The clearest first summary is what happened, when it started, and what treatment, ER care, or diagnosis followed.
Where you were treated
ER notes, office records, imaging, pharmacy history, and discharge papers usually anchor the timeline better than memory alone.
Sources
Official sources used across the site
- DailyMed: Ozempic prescribing information
Primary label source for severe gastrointestinal adverse reactions, retinopathy language, and boxed-warning statements.
- FDA label: Wegovy (semaglutide)
Current FDA label revised February 2026 for severe GI reactions, pregnancy language, diabetic retinopathy monitoring, thyroid boxed-warning language, and removal of suicidal-behavior language.
- NIDDK: Gastroparesis overview
NIH patient overview explaining delayed gastric emptying, symptoms, diagnosis, and treatment topics.
- NIDDK: Symptoms & causes of gastroparesis
NIH reference for common symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain.
Frequently Asked
Common questions
Can this be reviewed as a possible claim?+
Possibly. It depends on the medication involved, what happened, the timing, the records available, and other individual facts.
What happens after I submit the form?+
Your inquiry is received with the details you provide. If additional information is needed, someone can contact you using the email or phone number you submit.
What information should I have ready?+
If you have it, the most helpful information is the medication name, the dates you took it, the symptoms you experienced, and any treatment or diagnosis you received.
What if my symptoms feel urgent?+
Urgent or worsening symptoms should be evaluated by a licensed medical professional right away. Emergency situations should go to emergency care first, not a website form.